Xolair® (omalizumab)
More information
Great Britain (GB) Summary of Product Characteristics (SmPC) for the 75 mg pre-filled syringe and autoinjector pen, 150 mg pre-filled syringe and autoinjector pen, and 300 mg pre-filled syringe and autoinjector pen for Xolair.
Great Britain (GB) Patient Information Leaflet (PIL) for the 75 mg pre-filled syringe and autoinjector pen, 150 mg pre-filled syringe and autoinjector pen, and 300 mg pre-filled syringe and autoinjector pen for Xolair.
These links will take you to the electronic medicines compendium Great Britain (emc) website, which is a non-Novartis website.
Northern Ireland (NI) Summary of Product Characteristics (SmPC) for the 75 mg pre-filled syringe and autoinjector pen, 150 mg pre-filled syringe and autoinjector pen, and 300 mg pre-filled syringe and autoinjector pen for Xolair.
Northern Ireland (NI) Patient Information Leaflet (PIL) for the 75 mg pre-filled syringe and 150 mg pre-filled syringe for Xolair.
These links will take you to the electronic medicines compendium Northern Ireland (emc) website, which is a non-Novartis website.
UK | October 2024 | FA-11221723
Reporting side-effects
If you get side-effects with any medication you are taking, talk to your doctor, pharmacist or nurse. This includes any possible side-effects not listed in the information leaflet that comes in the pack. You can report side-effects via the Yellow Card Scheme at www.mhra.gov.uk/yellowcard.
By reporting side-effects you can help provide more information on the safety of your medication.
